NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading AMPH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a durable compounder with some near-term challenges. The current thesis state is intact, but recent performance has shifted to a mixed signal, indicating potential volatility ahead.
The market appears to price AMPH as cheap compared to its peers, with an expectations gap suggesting that investors may not fully anticipate future performance improvements. The valuation indicates a low premium versus peers, reflecting a cautious outlook.
Management has consistently prioritized revenue growth, but results show limited progress. Operating income has declined, while cash from operations has improved, indicating some positive momentum despite overall performance challenges.
The long-term thesis hinges on sector performance, particularly the outcomes of major players like HLN, TEVA, and ZTS. Positive earnings from these companies could support AMPH, while misses could lead to a decline in momentum.
In the next 1 to 3 years, AMPH's performance will depend on both its operational improvements and the broader healthcare sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'mild_favorable'.
Yes, our read has weakened. The latest earnings report showed a significant miss. This performance raises concerns about the company's ability to meet expectations.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: BAQSIMI is a key revenue driver. Continued growth is vital for overall revenue health.
Confirms:BAQSIMI sales exceed $40 million in Q2 2026.
Disproves:BAQSIMI sales fall below $30 million in Q2 2026.
Why it matters: Better operating income is important for financial health. It shows how well the company controls costs.
Confirms:Operating income went up to $13.6 million in Q1.
Disproves:Operating income drops or stays below $13.6 million in Q2.
Why it matters: Missing earnings again would show ongoing problems with financial goals.
Confirms:Q2 earnings miss analyst expectations by more than 10%.
Disproves:Q2 earnings meet or are better than what analysts expect.
Why it matters: This will show if Amphastar's revenue growth is improving or continuing to lag.
Confirms one read:In Q2 2026, net revenues are over $180 million. This shows revenue growth is getting better.
Confirms the other:In Q2 2026, net revenues are under $170 million. This points to ongoing revenue problems.
Why it matters: FDA approvals can greatly increase revenue and market position. This is key for Amphastar's growth.
Confirms:FDA approved a new pipeline product in Q2 2026.
Disproves:No FDA approvals announced for new pipeline products in Q2 2026.
Why it matters: Earnings per share is a key sign of profit. Meeting expectations can help investor trust.
Confirms:Q2 earnings per share meet or exceed $0.14.
Disproves:Q2 earnings per share fall below $0.14.
Why it matters: FDA approvals can greatly increase revenue and market presence. This is key for Amphastar's growth.
Confirms:Announcement of FDA approval for at least one new product in Q3 2026.
Disproves:No FDA approvals were announced in Q3 2026. This shows there are regulatory problems.
Why it matters: Strong revenue growth would show that Amphastar is improving its sales momentum. This is important for investor confidence.
Confirms:Q2 net revenues were over $180 million. This shows more than 5% growth from last year.
Disproves:Q2 net revenues were below $180 million. This shows less than 5% growth from last year.
Why it matters: Better operating income means better cost management. This helps with long-term growth.
Confirms:Operating income was over $20 million for Q2 2026.
Disproves:Operating income was below $20 million for Q2 2026.
Why it matters: Steady cash flow helps Amphastar grow and stay financially stable.
Confirms:Cash from operations exceeds $50 million in Q2 2026, confirming strong cash flow.
Disproves:Cash from operations is below $45 million. This shows possible cash flow problems.
